Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, De Sanctis C, Rigon F, Zamboni G, Bernasconi S
Pediatric Endocrine Unit, University of Verona, Italy.
Acta Paediatr. 1994 Oct;83(10):1052-6. doi: 10.1111/j.1651-2227.1994.tb12984.x.
In order to evaluate the effects of two long-acting luteinizing hormone-releasing hormone agonists on growth, bone maturation and final height in girls with central precocious puberty, we analyzed growth data from 40 girls (15 treated with buserelin intranasal spray (group A), 15 treated with triptorelin depot im every 28 days (group B) and 10 untreated (group C)). Patients in group A started treatment when chronological age (CA) was 7.7 +/- 0.9 years, bone age (BA) was 10.2 +/- 1.1 years and height was 131.9 +/- 5.0 cm. Patients in group B started therapy when CA was 7.6 +/- 0.5 years, BA 9.8 +/- 1.0 years and height 133.2 +/- 7.6 cm. The diagnosis of untreated patients (group C) was made when CA was 7.2 +/- 0.9 years, BA 9.6 +/- 2.2 years and height 130.2 +/- 8.6 cm. Both luteinizing hormone-releasing hormone agonists appeared to control precocious puberty. Final height in group B (160.6 +/- 5.7 cm) was significantly higher than that of group A (153.2 +/- 5.0 cm: p < 0.05) and group C (149.6 +/- 6.3; p < 0.01), whereas the difference between groups A and C was not statistically significant. In group B a positive difference was observed between final height (160.6 +/- 5.7 cm) and target height (157.6 +/- 5.9 cm) (ns); on the contrary, in groups A and C, final height was lower than target height (155.5 +/- 5.3 and 156.4 +/- 1.3 cm, respectively), but only in group C the difference was statistically significant (p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
为了评估两种长效促黄体生成激素释放激素激动剂对中枢性性早熟女孩生长、骨骼成熟及最终身高的影响，我们分析了40名女孩的生长数据（15名接受布舍瑞林鼻喷雾剂治疗（A组），15名每28天接受一次曲普瑞林长效注射剂治疗（B组），10名未接受治疗（C组））。A组患者开始治疗时的实足年龄（CA）为7.7±0.9岁，骨龄（BA）为10.2±1.1岁，身高为131.9±5.0厘米。B组患者开始治疗时CA为7.6±0.5岁，BA为9.8±1.0岁，身高为133.2±7.6厘米。未接受治疗患者（C组）确诊时CA为7.2±0.9岁，BA为9.6±2.2岁，身高为130.2±8.6厘米。两种促黄体生成激素释放激素激动剂似乎都能控制性早熟。B组的最终身高（160.6±5.7厘米）显著高于A组（153.2±5.0厘米：p<0.05）和C组（149.6±6.3厘米；p<0.01），而A组和C组之间的差异无统计学意义。B组最终身高（160.6±5.7厘米）与靶身高（157.6±5.9厘米）之间观察到正差值（无统计学意义）；相反，A组和C组的最终身高低于靶身高（分别为155.5±5.3厘米和156.4±1.3厘米），但只有C组的差异有统计学意义（p<0.01）。（摘要截选至250词）
